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ABSTRACT 
The aim of this study was to develop and characterise an intranasal delivery system for 
amantadine (AMT).  Optimal formulations (F) consisted of a thermosensitive polymer 
Pluronic® 127 (P127) and either carboxy methyl cellulose (CMC) or chitosan (CS) which 
demonstrated gel-transition at nasal cavity temperatures (34 °C ± 1 °C). Rheologically, the loss 
tangent (Tan δ) confirmed a three-stage gelation phenomena at 34 °C ± 1 °C and non-
Newtonian behaviour.  Storage of FCMC and FCS at 4 °C for 8 weeks resulted in repeatable 
release profiles at 34 °C when sampled, with a Fickian mechanism earlier on but moving 
towards anomalous transport by week 8.  Polymers (P127, CMC and CS) demonstrated no 
significant cellular toxicity to human nasal epithelial cells up to 4 mg/mL and up to 1 mM for 
AMT (IC50: 4.5 mM ± 0.05 mM). FCMC and FCS demonstrated slower release across an in-
vitro human nasal airway model (43-44 % vs 79 % ± 4.58 % for AMT).  Using a human nasal 
cast model, deposition into the olfactory regions (potential nose-to-brain) was demonstrated 
upon nozzle insertion (5 mm) whereas tilting of the head forward (15°) resulted in greater 
deposition in the bulk of the nasal cavity.  
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INTRODUCTION 
Parkinson’s disease (PD) is an ageing associated progressive neurological disorder and 
affects 1.5 % of the population over 65-years of age 1, with age-adjusted prevalence rates 
thought to be around 150 per 100,000 with a suggested mean onset in the 70’s 1. Ageing is the 
largest single risk factor for the development of PD and the pathogenesis of PD is composed 
of a range of events leading towards neuronal apoptosis, primarily of degradation of dopamine 
neurones in the sustantia nigra. The mainstay of clinical drug therapy focuses on increases the 
levels of dopamine (DA) in the brain, with oral dosing of levodopa being the most commonly 
used to pharmacological intervention treatment to reverse the symptoms of PD.  It is also 
common to use adjunct therapies in conjunction with levodopa, such as the weak NMDA-type 
receptor antagonist amantadine, which can aid in blocking dopamine reuptake. 
One of the major complications of PD is the emergence of dysphagia affecting the ability to 
ingest/swallow and is a thought to affect between 45-95 % of PD patients 1,2 and has significant 
implications for orally dosed therapeutics such as amantadine and other anti-Parkinsonian 
therapeutics agents.  Furthermore the occurrence of bradykinesia and morning akinesia is often 
associated with delayed gastric emptying following the oral administration of anti-
Parkinsonian therapeutics.  This is again confounded by the use of dopaminergic and other 
concomitant meditation interventions.  At least 24% of PD patients are thought to suffer from 
gastroparesis, the delay in empting of the stomach, which will inevitably impact upon clinical 
outcome of any orally administered medication. A more recent approach for therapeutic 
delivery is through the intranasal route to obtain systemic deposition as a practical alternative 
to oral and parenteral routes 3,4.   
The primary function of the nasal cavity is respiration and olfaction. The nasal cavity (in 
humans) is divided in to two symmetrical halves by a septum with each cavity sub-dived into 
four areas namely vestibules, atrium, respiratory region and olfactory regions.  With a surface 
area of 150 cm2, total volume of 15-20 mL the nasal cavity provides an optimal absorption area 
for drugs into the systemic circulations which would inevitably enhance the bioavailability of 
the therapeutic agent, particularly those which demonstrate poor oral absorption (intestinal 
permeation) or significant first-pass metabolism (extra-hepatic and hepatic) 5,6.  Although 
originally exploited for the delivery of locally acting agents (allergic of infections rhinitis, nasal 
pluposos and sinusitis) the highly vascularised nature of the nasal cavity has provided a portal 
for systemic delivery of small molecules and biomolecules 7. The nasal cavity can provide 
larger surface area for rapid systemic absorption due to its highly vascularised surface 8. This 
non-invasive route not only provides rapid onset of action, but often increased bioavailability 
in low doses as it bypasses the first pass metabolism 9.  
Although intranasal drug delivery offers many advantages, one of the main limitations is the 
short residence time of the formulation in the nasal cavity, as a result of mucociliary clearance 
(MCC) 10.  This movement involves the beating of mucocilia at a frequency of 1,000 strokes 
per minute and hence movement of mucus of 5 mm/minute 11.  Thus the clearance of any 
nasally administered formulation further back towards to the nasopharynx is often a limiting 
factor in clinical administration and results in a short nasal residency half-life of 15-20 minutes 
12. 
An ideal formulation would be one that was capable of prolonging residence time within the 
nasal cavity and therefore enhance the bioavailability of the drug.  To achieve this goal, the use 
of intelligent polymer based systems have now become more commonplace in this field and 
particularly the use of responsive systems which may respond to the nasal cavity temperature 
13-22 or pH 23-27 have increased amongst researchers.  Furthermore, the use of mucoadhesive 
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polymers 4,27-33 to enhance the adhesion of the formulations onto the nasal mucosa has further 
demonstrated the ability to prolong contact time with the mucosa and hence increase 
bioavailability 10,15,18,23,34-36. 
The primary aim of this study was to develop an intranasal thermoresponsive hydrogel based 
delivery system for the delivery of anti-Parkinson’s drugs, using amantadine as a model 
candidate drug.  The study objectives were to utilise thermoresponsive polymers, for example 
Pluronic F127 (P127) 13, mucoadhesive polymers (carboxymethyl cellulose and chitosan) and 
surfactant (PEG4000 and PEG 12000) to aid and enhance formulation delivery and retention 
within the nasal cavity using a multi-dose nasal spray and human nasal cast.  In order to develop 
and assess the formulations a range of studies were conducted and included rheological, 
stability, biological compatibility and nasal targeting of the formulations. 
METHODS 
Materials 
Eagle’s Minimum Essential Medium (MEM), Dulbecco’s phosphate buffered saline (PBS), L-
glutamine 200 mM, non-essential amino acids (NEAA), penicillin/streptomycin and trypsin-
EDTA solution were obtained from PAA Laboratories (Austria); fetal bovine serum (FBS) 
(Labtech Intl Ltd. East Essex, UK); polyethylene glycol 4000 (PEG4000), polyethylene glycol 
12000 (PEG12000),  chitosan-medium molecular weight (CS), sodium chloride, potassium 
chloride, magnesium sulphate, calcium chloride, acetonitrile, orthophosphoric acid, acetic acid, 
ethanol, sodium hydroxide, potassium chloride and sodium chloride were obtained from Fisher 
Scientific (Loughborough, UK); gentamycin, (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide) MTT, Trypan blue dye, Pluronic® F127 (P127), sodium carboxymethyl 
cellulose (CMC), amantadine hydrochloride (AMT), sodium metabisulphate, mucin from 
porcine stomach, boric acid, dimethyl sulfoxide (DMSO) and benzalkonium chloride were 
obtained from Sigma-Aldrich (St. Louis, MO, USA).  
Formulation development 
Formulations were initially prepared by a modified ‘Cold method’ approach as originally 
described by Schmolka (1973) 13. Briefly fixed quantities of excipients were utilised in all 
formulations and consisted of d-sorbitol (humectant) (0.5 % w/v), sodium metabisulphate 
(antioxidant) (0.1 % w/v) and benzalkonium chloride (surfactant) (0.1 % w/v). Additional 
polymers were incorporated and included mucoadhesives (CMC and CS) and permeation 
enhancers37/modulators of gelation temperature14,38 (PEG4000 and PEG 12000) at 
concentrations between 0.5-1.5 % w/v.  These components were combined with ultrapure water 
under constant stirring.  This was followed by AMT (0.5-1.5 % w/v) and the resulting solution 
was kept in an ice bath for 2 hours prior to the dropwise of P127 (15-20 %) and storage at 4 °C 
for 12 hours.  Prior to use, the pH of all formulations were adjusted to 5.516,39. Formulations 
were developed according to variation in the concentration of P127, mucoadhesive polymer, 
and drug content. 
Sol-gel transition (Tsol-gel)  
A modified method described by Zaki et al. 8 was used to determine the sol-gel transition 
temperature (Tsol-gel). A sample of each formulation (1 g) was transferred to a glass vial and 
heated in a dry block (Techne Dri-Block ® DB-2D), initiated at 20 °C and increased by 1 °C 
after every 5 minutes of equilibration time. The Tsol-gel point was defined as the temperature 
whereby the upper meniscus of the gel did not move upon tilting the vial by 90 ° and this was 
used to demark optimal formulations. The optimal subset of formulations were then further 
characterised. 
 6 
 
Rheological characterisation 
To assess the rheological properties of the formulations, rheological measurements were 
carried out on AR-G2 Rheometer (TA Instruments, USA), using parallel plate geometry with 
40 mm steel plates having a gap 1.0 mm. The approximate sample volume used was 1.26 mL 
and the instrument was used in the oscillatory mode in the linear viscoelastic range of the 
sample. Steady state behavior was assessed at ambient (18 °C) and nasal (34 °C) temperatures 
over a shear rate range from 0.1 to 100 s-1.  
To quantify the rheological properties, the Ostwald-de Waele relationship (often called 
the power law) was applied to relate the shear stress (σ) is related to a consistency coefficient 
(k), the shear rate (ࢽሶ) and an index value (n):   
࣌ ൌ ࢑ࢽሶ࢔ 
which is applicable to the formulations in light of the constant shear viscosity curves. In the 
context of rheology, the index value can be used to determine the type behavioural flow, with 
Newtonian behaviour when n = 1. When the magnitude of n is < 1, the underlying rheological 
process is shear-thinning (pseudoplastic flow) and then when n > 1 the fluid is shear-thickening.  
 
In-vitro mucoadhesion   
The method of Nakamura et al. (1996) 24 was adapted to measure the mucoadhesion of 
the formulation systems.  Briefly, 100 g of a hot 1 % agar and 2 % mucin mixture in PBS (pH 
6.0) was cast onto a glass plate and left to gel at 4 °C for 12 hours. The gel plate was then 
equilibrated at 34 °C for 1 hour followed by the application of a 250 µL sample of each 
formulation when the plate was kept at a 45° angle at 34 °C. This process was repeated using a 
1 % agar mixture (without mucin) and the mucoadhesion of the formulations were calculated 
by a ‘displacement’ value (measured in cm) reflecting the difference in gel movement in the 
presence and absence of 2 % mucin. 
AMT derivatisation and HPLC detection  
To quantify the release of AMT from the formulations, a pre-column derivatisation 
method for memantine was modified in order to enable detection of AMT 40. Briefly, to 50 µL 
of sample or standard solution of AMT, 40 µL of 0.015 M FMOC and 50 µL of 0.5 M borate 
buffer were added and kept at room temperature for 20 minutes prior to the addition of 360 µL 
of a 0.05M borate buffer:acetonitrile (50:50 v/v) diluent. A Shimadzu HPLC system was used 
with a Phenomenex Luna C18 (150 × 4.6 mm) 5 µm column. The mobile phase consisted of 
phosphate buffer:acetonitrile (20:80 v/v).  The column was maintained at 30 °C and 10 µL 
injected.  The flow rate was maintained at 2 mL/minute with run time of 7 minutes. The UV 
detection of derivatised AMT was measured at 265 nm. The intra/inter-day precision was 
determined and the limit of detection (LOD) and limit of quantitation (LOQ) were calibrated 
according to ICH (QR (R1)) recommendations 41. 
Stability assessment 
Optimised formulations were stored in stability cabinets maintained at 4 ± 1 °C (Sanyo 
Medicool, UK) and 25 ± 2 °C (Firlabo, France) at a humidity of 60 % ± 5 %. The stability of 
the formulation was assessed based on the gelation of a sample of the formulation at 34 °C 
within 5 minutes, followed by assessment of the extent of drug release. 
The release of AMT from the formulations were assessed by a ‘membrane-less’ diffusion 
system 20,42,43.  A mass of formulation (0.25 g) appropriate for the nasal cavity volume was 
transferred to a glass vial and allowed to equilibrate in a dry block at 34 °C. Artificial nasal 
electrolyte (ANE) (0.8 g/L NaCl, 3 g/L KCl, and 0.45 g/L CaCl2, pH 6.8) 44 was used as release 
media and 100 µL transferred onto the gelled formulation. This volume was completely 
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withdraw and replaced with fresh ANE at each time point. Samples were analysed by a pre-
column derivatisation method followed by HPLC analysis. 
In-vitro drug release kinetics 
Several kinetic drug release mathematical models were used to assess drug release from the 
formulations. The best-fit to the mathematical models described below confirmed the 
appropriate release kinetics: 
Higuchi model: ெ೟ெಮ ൌ ݇ܪ ∙ ݐ
భ
మ 
where Mt/M∞ is the drug fraction released at time t and kH is the Higuchi constant. 
Zero order model: ெ೟ெಮ ൌ ݇଴ ∙ t 
where Mt/M∞ is the drug fraction released at time t and k0 is the zero-order release constant. 
First order model: ெ೟ெಮ ൌ 1 െ ݁
ି௞భ௧ 
where Mt/M∞ is the drug fraction released at time t and k1 is the first-order release constant. 
Power law: ெ೟ெಮ ൌ ݇ܭܲ ∙ ݐ
௡ 
where Mt/M∞ is the drug fraction released at time t, kKP is a kinetic constant which describes 
the structural and geometrical elements of the formulations and n is the release exponents 
which is used to indicate the mechanism of drug release. The power law, otherwise known as 
the Korsmeyer-Peppas power law 45, has been used in many pharmaceutical formulations 46-49. 
The value of n is important in understanding the mechanism of release when it is unknown and 
often polymeric formulations can be categorised accordingly to this scale. When n ≤ 0.45 drug 
release is diffusion controlled and sometimes referred to as Fickian diffusion and when n > 
0.89 the diffusion is indicative of erosion controlled drug release or class-II kinetics. For 
situations where 0.45 < n ≤ 0.89 the diffusion is a complex mixture of both processes and often 
termed anomalous transport. In all cases this is based on the assumption of release from a 
cylinder and applied to cumulative release rates < 60 % 45. 
Human nasal epithelial cell culture model  
The immortalised human nasal epithelial cell line RPMI 2650, was used to assess the 
compatibility of the formulations with human nasal epithelia and to develop an in-vitro nasal 
epithelial cell culture model 50 to assess drug release/transport.  Cells were grown in MEM 
supplemented with 10 % FBS, 1 % L-glutamine, 1 % NEAA, 1% penicillin-G/streptomycin in 
a humidified 37 °C incubator with 5 % (v/v) CO2 51. The media was changed every 2 days.  
 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) assay 
To assess cellular toxicity, RPMI 2650 cells were seeded at a density of 4x104 cells per well of 
a 96-well plate and allowed to attach for 24 hours. The media was removed and replaced with 
200 µL of media containing either AMT (0.01-50,000 µM), mucoadhesive polymers or P127 
(10-4000 µg/mL) and incubated for 24 hours at 37 °C in a 5 % (v/v) CO2 humidified air 
environment. Subsequently 20 µL of 5 mg/mL MTT dissolved in PBS was added to each well 
and incubated at 37 °C in a humidified air environment for 4 hours. After incubation the 
medium was removed and 100 µL of DMSO was added and the plates left to incubate for 15 
minutes in the dark.  The UV-absorbance of the formazan product was determined at 595 nm. 
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Each concentration was assayed in eight wells and run in three independent experiments and 
results expressed as percentage cytotoxicity relative to a control (0.5% DMSO).   
Human nasal epitheial airway cell culture model: AMT transport 
To assess the release and transport of AMT from formulations, an in-vitro nasal epithelial 
airway cell culture model was developed with RPMI 2650 cells seeded onto collagen-coated 
6-well permeable inserts (ThinCertsTM) at a seeding density of 4x105 cells/cm2 52 50 and grown 
for 14 days.  On days 10-14 an air-liquid interface (ALI) was initiated with the removal of 
apical media.  The integrity of the monolayer was determined by measuring the trans-epithelial 
electrical resistance (TEER) using an EVOM epithelial voltohmmeter (World Precision 
Instruments Inc.). Inserts were deemed acceptable where the TEER value was above 180 Ω.cm2 
52 50. 
Immediately prior to the start of the transport study, maintenance media was replaced with 
transport media (HBSS with 25 mM HEPES) and the cells left to acclimatise for 30 minutes in 
a humidified 37 °C incubator with 5% (v/v) CO2.  A 1 mL sample of formulation was placed 
into the apical chamber, after removal of transport media from apical and basolateral 
compartment, and returned to the incubator for 5 minutes.  Once gelled, fresh transport media 
was placed into the basolateral chamber and 250 µL samples withdrawn at 5, 15, 30, 60, 120, 
150 and 180 minutes and replaced with fresh pre-warmed media.  Withdrawn samples were 
derivatised and AMT release quantified by HPLC analysis. 
Nasal spray systems: droplet size distribution 
To assess the potential in-vivo deposition characteristics of the proposed nasal formulation, a 
multi-dose pump spray delivery system was employed to characterise the formulation droplet 
size distribution using a laser diffraction technique.  The HELOS (Sympatec, UK) system was 
used with an R3 lens (measuring range 0.5-175 µm).  The nasal pump was vertically mounted 
3 cm away from the laser path and a vacuum source was mounted anterior to the pump system.  
The pump systems were pre-actuated prior to mounting, and actuated three times to detect the 
particle size distribution.   Data was reported as volume diameters at 10 %, 50 % and 90 % of 
the cumulative undersized volumes. Span was calculated as: [(Dv90-Dv10)/Dv50]. 
Nasal spray system: human nasal cast deposition  
To assess the potential in-vivo deposition characteristics of the proposed nasal formulation, a 
multi-dose pump spray delivery system was employed to assess the deposition of formulations 
into an anatomically correct human nasal cast model (Koken Ltd, Japan).  The inner surface of 
each nostril was evenly coated in a water-indicated dye (Kolor Kut, USA).  Formulations were 
loaded into the spray pump, pre-actuated, before one actuation was delivered into the nasal cast 
where the cast was fixed in an upright head position.  The impact of spray angle and nostril 
insertion depth on nasal deposition was analysed through photographing colour changes.  The 
captured images were subsequently processed through pixel quantification software to quantify 
the deposition patterns and calculate the deposition surface area 53.  The depositions of within 
the nasal cast was classified according to the predominate regions of deposition within the cast, 
i.e. lower nasal regions (nasal vestibule), the middle/upper nasal regions (turbinates) and the 
olfactory regions were assessed. 
Statistical analysis 
Unless otherwise stated, three independent experiments were carried out for each study. 
Statistical significance was evaluated by one-way ANOVA or paired two-tail Students t-test 
using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California 
USA, www.graphpad.com). Calculations of IC50 were determined using a four-parameter 
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logistic sigmoidal fitting function within GraphPad Prism.  Unless otherwise states, data is 
reported as mean ± standard deviation (SD). A significance level (p-value) of < 0.05 was 
considered as statistically significant. 
RESULTS AND DISCUSSION 
The treatment of age-associated degenerative CNS disorders such as Parkinson’s 
diseases, poses particular difficulties in the design of appropriate drug delivery systems capable 
of overcoming the hindrances associated with dyskinesia and dystonia that are inherent in 
current pharmacological interventions for PD.  Although reformulation of existing orally dosed 
formulations may provide some benefit there is an inherent need to provide an alternative 
delivery routes of a range of CNS disorders which can both provide ease of clinical use but 
also improve the bioavailability of the therapeutic. 
The nasal mucosa fulfils this purpose in light of the large and vascularised route of access for 
drugs to the systemic circulation and can provide a relatively non-invasive approach to delivery 
drugs. 
 
A key concern of any nasal administered formulation is the residency of the formulation within 
the nasal cavity. Existing formulations are often associated with a nasal drip or ‘run-off’ effect 
which potentially diminish the bioavailability of nasal formation.  A novel development in this 
area has been the formulation of intelligent response based hydrogel nasal formulations which 
act to enhance residency within the nasal cavity 13-27. 
 
Sol-gel transition (Tsol-gel)  
The initial screening and optimisation resulting in 32 formulations, of which 3 
demonstrated optimal gelation at the nasal cavity temperature of 34 °C ± 1°C 54.  These 
formulations were identified as FCMC (1 % w/v CMC), FPEG (1 % w/v PEG4000) and FCS 
(0.1 % w/v chitosan) and which all contained 17 % w/v P172 and 1% w/v amantadine (in 
addition to excipients). 
 
Rheological behaviour 
When assessing the properties of thermoresponsive gel-like systems, the 
storage/elasticity modulus (G′) and the loss modulus (G′′) are key metrics to describing the 
rheology of the formulation.  The elasticity modulus is an important metric in this regard and 
measures the energy stored and which is subsequently recovered for each cycle of deformation 
55. It presents with lower values with reduced temperatures but significantly increases with an 
increase in temperature, and the point at which G′ overtakes G′′ indicates the initiation of the 
gelation phenomena. To assess this phase transition the ratio of G′′ and G′ (the loss tangent, 
Tan δ) was used, and where a phase-transition occurs an abrupt change in Tan δ is observed 
with values of < 1 indicating a greater G′ compared to G′′, indicative of gel formation.  This 
phase transition is often associated with three distinct phases: (i) an initial stable liquid phase 
plateau at low temperatures; (ii) an abrupt transition phase during the gelation process; (iii) a 
late stage stable gel plateau. 
 
All formulation demonstrated a gelation phenomenon, which initiated at approximately 
26-28 °C, and was preceded by the stable plateau region (Figure 1). FCS and FCMC (Figure 
1A) demonstrated a complete profile with three distinct phases culminating in a stable gel 
formulation, whereas FPEG (Figure 1A) only demonstrated two phases, plateau followed by a 
partial gelation phase, but did not form a stable a gel at the termination of the study (34 °C).  
The rate of gelation is also a key determinant of residency within the nasal cavity and this was 
assessed through a time-sweep analysis at a fixed temperature (34 °C).  FCMC demonstrated 
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the quickest gelation of 28 ± 2 seconds which was followed by FCS (37 ± 3 seconds) and FPEG 
(68.5 seconds) (Figure 1B). 
 
At nasal cavity temperatures, a significant shear thinning behaviour was observed in all 
formulations, indicative of temperature-induced gel formation when compared to ambient 
temperatures (Figure 2), with viscosities for 34 °C being statistically significantly different to 
those at 18 °C (P < 0.0001).  Furthermore, at 34 °C no significant difference in viscosity was 
reported over the shear rate studied (p = 0.227), however FPEG demonstrated a statistically 
significant lower viscosity compared to FCS and FCMC (P < 0.01). 
 
As the shear rate increased from 0.091 to 100 s-1, the viscosity of the formulations 
dropped by 990-fold (FCMC), 409-fold (FCS) and 207-fold (FPEG) (Figure 2).  However, all 
formulations exhibited non-Newtonian behaviour at nasal temperatures compared to 
Newtonian behaviour at ambient temperatures (Table 1). 
From an interpretation of the Ostwald model, the gel structure can be changed as a result of 
any deformation induced changes in the gel particles, through changes in the alignment of the 
polymer chains and also any changes in the interactions between polymer chain segments and 
any side chains. Therefore, upon heating the values of n will be lower in for stronger gels due 
to an increase in the noncovalent forces of between neighbouring particles 56.  
 
It was also apparent that the presence of different mucoadhesives can significantly alter 
the behaviour of the formulations.  For examples, the viscosity of FCMC was always higher 
than all other formulations, and particularly at 34 °C where there is an approximate 8-fold 
difference between FCMC and FPEG. Furthermore, the FCMC demonstrated a much lower n-
value compared to FCS and FPEG (Table 1), suggesting a stronger gel formation at 34 °C.  
This phase represents the gradual conversion into a highly viscous/solid state.  During this 
phase the intricate hydrogen-binding network between the unimers of F127 and water 
molecules are disrupted and drives the formation of micelles, which further aggregate to form 
the physical gel-like structure. 57. On the basis of 13C NMR studies Pisal 58 suggested that at 
high temperature, conformational changes in the methyl group of the polyoxypropylene within 
the hydrophilic micellar region and in the motion of the hydrophilic end chains takes place. 
This results in dehydration and end chain friction, which causes the gelation.  
 
In-vitro mucoadhesion 
Mucoadhesion is defined as a state where at least one biological material is held with 
another material for a prolonged period of time 59.  In the context of drug delivery, this can be 
defined as the adhesion of an artificial material (such as a polymer system) to a biological 
substrate material 60.  We assessed the mucoadhesion of optimized formulations using an 
inclined-plate method in the presence and absence of mucin 24, with mucoadhesion assumed to 
have occurred if the displacement of the formulation in the absence of mucin is greater than in 
the presence of mucin. 
 
The displacement transfer test demonstrated that all formulations showed a statistically 
significant (P ≤ 0.001) displacement in the absence of mucin (Figure 3).  The difference 
between the absence and presence of mucin is indicative of the displacement effect and FCMC 
demonstrated the least extent of displacement (2.26 cm) with FPEG demonstrating the greatest 
extent of displacement (3.8 cm). 
 
The superiority of FCMC and FCS, compared to FPEG, is presumed to be a function of the 
enhanced rheological properties FCMC and FCS possess (Figure 1 and 2).  The fact that 
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displacement is observed in the absence of mucin would indicated that the use of is able to 
recover some of the mucoadhesive properties of the mucoadhesive polymers included within 
the formations, and although known to show less biophysical properties as compared to native 
mucin, this purified mucin has less batch-to-batch variation and hence provides better 
reproducibility in measuring mucoadhesive force 61. 
AMT derivatisation and HPLC detection  
The HPLC was successfully able to detect the derivatisation of AMT with a retention 
time of 4.4 minutes.  Percentage RSD for system precision (0.120 %) and method precision 
(0.121 %) were within the acceptable limits of 1 % and 2 % respectively.  
 
The linearity response of amantadine was determined using concentrations ranging 
from 0.0078 to 1.0 mg/mL and the response was linear over the specified range with a 
correlation coefficient of  0.9998, a slope of 1385904 ± 33080 and an intercept of -13515 ± 
1045.  The validity was verified by ANOVA with no deviation from linearity. 
 
Stability assessment 
To assess the stability of the optimised formulations, batches were prepared and stored 
in stability cabinets at 25 °C/60 % RH and 4 °C for 8 weeks, with sampling at weekly intervals 
followed by assessment of AMT release conducted at nasal temperatures (34 °C).  A 
prerequisite for conducting release studies was the successful gelation of the stability samples 
prior to initiation of release studies. 
All formulations stored at 4 °C demonstrated successful sol-gel transition prior to the initiation 
of the release studies, confirming the thermoresponsive nature of the gel systems was 
maintained during the stability study duration.  However only FCS demonstrated successful 
sol-gel transition when stored at 25 °C/60 % RH for 2 weeks, confirming that storage of 
formulations would be more appropriate at ‘refrigerated’ conditions to ensure stability of the 
products. 
 
The cumulative percentage release at preparation and after 1 week storage at 4 °C were not 
significantly different for all formulations, reaching 15-17 % release (Figure 4A).  Following 
8 weeks storage at 4 °C, the quantity of AMT released from FCMS (16.15 % ± 0.82 %) was 
not significantly different to that at week 0 (16.86 % ± 1.13 %) (Figure 4B), however at earlier 
time-points during the release study (30-120 minutes) significant differences (p < 0.05) in the 
AMT quantity released were apparent (Figure 4B).  For FCS, the amount of AMT released 
following 8 weeks storage at 4 °C (18 % ± 0.99 %) was significantly (p < 0.05) greater than 
that at week 0 (15.32 % ± 0.30 %) (Figure 4B).  Significant differences in the release profile 
were also apparent during the initial phases of the release study (30-60 minutes) (Figure 4B). 
 
As the formulations presented are inherently based on ‘swellable’ type polymer systems, the 
diffusion was also modelled by the Korsmeyer-Peppas power law and generally demonstrated 
Fickian-type diffusion early on (except for FCS).  By week 8 this had moved towards 
anomalous transport (Table 2), whereby drug diffusion and the polymer relaxation were 
contributing to the overall release kinetics. 
 
 
The movement towards anomalous transport can be explained by considering the relationships 
between the two driving forces influences the diffusional process within the polymer system, 
namely the rate of solvent diffusion (RD) and the rate at which polymer chains relax (RR).   
 12 
 
In Fickian-type diffusion (case-I), RD is much slower compared RR.  For non-Fickian diffusion 
(case II, anaomolous and super case II) the main differences lies with the RD whereby for case 
II RR >> RD, for anomalous-type kinetics RD ≈ RR and for super case II  RD >> RR 62-65.  Initially, 
formulations demonstrated Fickian-type diffusion (Table 2) but the Korsmeyer-Peppas 
exponent increased over the stability period to > 0.5 by week 8 moving towards anomalous 
transport (Table 2).  This would suggest that polymer relaxation (swelling/erosion) plays a 
critical role in the release of AMT at earlier stability time points.  The mathematical description 
and modelling of the casual factors for anomalous transport is challenging, and is beyond the 
scope of this study however a detailed review has been published discussing this issue 66.   
 
The mass transport of AMT into the polymer network can be assumed to be comprised of 3 
processes 67,68, whereby the solvent (water) is absorbed onto the surface of the polymer.  The 
solvent molecules may then enter the lattice network of the polymer, which causes a ‘swelling’ 
of the network and elongation.  This elongation is then counter balanced by an elastic-
restrictive force to oppose the swelling.  Eventually a state of equilibrium is reached when both 
forces are balanced, these process can significantly alter the kinetics of drug diffusion through 
the polymer network and are highly influenced by time-scale associated structural changes in 
the polymer 69-72. The move towards anomalous transport over 8 weeks may suggest a polymer 
network time-associated affect 73,74, which becomes more apparent over the longer stability 
study.  The equilibrium between swelling and elastic-restrictive force within the polymer may 
be associated with a time-dependent equilibrium, where equilibrium is not established 
immediately75.  
Although the formulations are in liquid-phase during the stability storage period, the 
interactions between both mucoadhesive polymers and thermoresponsive polymers may 
influence eventual formulations of the polymer networks, altering the equilibrium processes 
and hence contributing towards the anomalous transport.  
Human nasal epithelial cell culture model: MTT assay 
To investigate the toxicity of amantadine and polymers used within the formulations, a 
cellular viability study was conducted using the human nasal epithelial cell line RPMI 2650.  
Cell viability was generally maintained for AMT up to 1 mM, with an IC50 of 4.6 mM ± 0.05 
mM (Figure 5A) when exposed for 24 hours.  For all polymers tested, no significant decrease 
in cellular viability was observed up to 4 mg/mL (Figure 5B-D) and confirmed the formulations 
developed would be tolerable, from a cellular toxicity perspective, to human nasal epithelia.  
Furthermore, no previous reports have examined the in vitro toxicity profile of AMT towards 
human nasal epithelia and our reports demonstrated that 1 mM would be suitable for prolonged 
(up to 24 hours) exposure.  
 
Human nasal epithelial airway cell culture model: AMT transport 
The in vitro release of AMT alone and from formulations was further assessed in an in 
vitro nasal epithelial airway cell culture model over 3 hours (Figure 6). 
In all formulations a statistically significant (p ≤ 0.01) release of 43-44 % was observed over 
the duration of the transport study in comparison to that of AMT (79 % ± 3.58 %) (Figure 6). 
The mechanism of release, as described by the Korsmeyer-Peppas power law, was modelled 
according to a super case-II effect (n > 0.89) where the sorption of solvent results in breaking 
of the polymer network (termed solvent crazing) 76 as a result of the swelling of the gel within 
the vitreous nucleus and can be a result of crosslinking density 77, drug loading 78 and 
copolymer composition 79.  The super-case II diffusion of AMT from all gel systems was 
surprising, and therefore the release mechanism of AMT from the formulations is not clear as 
it is beyond the limits of the power law.  It suggests that a rapid release of AMT occurred later 
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in the experiment resulting in rapid relaxation governing/controlled transport of AMT from the 
polymer network 80 81. The ionic composition of the media, comprising of a pH of 7.4, may 
have directly altered the state of ionisation within the polymer gel network, compared to the 
pH of the ANE (pH = 5.5) leading to an altered release profile, with the rapid release being a 
time-dependant reflection of the shift in equilibrium as the solvent (media) penetrates the 
polymer network 65,75.  
Nasal spray systems: droplet size distribution 
 Prevention of pulmonary deposition of nasally administered spray formulations is 
paramount to ensure residency within the nasal cavity.  Droplet size distribution is key in 
determining the potential for pulmonary deposition (< 2 µm) 82,83, however the droplet size is 
often dictated by the design of the orifice of the actuator device used to deliver the spray plume. 
For ensuring retention of drug within the nasal passages, droplet sizes of in-excess of 5 µm are 
recommended and represented our target cut-off 82,84.   
Our formulations all demonstrated a diameter in excess of the traditional cut-off of 5 µm. 
(Table 3). FCS demonstrated a 10% fraction of 7.27 µm ± 0.28 µm (Table 3) closest to the cut-
off for pulmonary deposition, whereas both FCMC and FPEG were above this.  FCS also 
demonstrated the smallest diameter (VMD = 92.41 µm ± 1.72 µm). However, when 
considering the span of particle sizes, FCS was the broadest (0.96 ± 0.30) with both FCMC and 
FPEG showing a smaller distribution spread (Table 3).  A one-way ANOVA confirmed droplet 
VMD were significantly different across all formulations (p < 0.0001), suggesting that the 
incorporation of different mucoadhesive polymers contributed to the differing polymer sizes 
with FCS demonstrating the small resulting droplets (92.41 µm ± 1.72 µm) and FCMC the 
largest (120.87 µm ± 0.59 µm).  When considering the viscosity of the polymers used in each 
formulation (Figure 1), CMC resulted in the most viscous formulations and this may have 
contributed to the larger particle sizes, with similar trends observed for CS and PEG. 
Nasal spray system: human nasal cast deposition  
To assess the potential in vivo application of formulations, FCS and FCMC were taken 
forward to assess spray deposition within a human nasal cast model. The angle of spray 
administration was altered from 60-80° and the impact on deposition patterns assed.  For both 
formulations the administration angle had a significant effect on deposition, with an increased 
angle (80°) having a significantly pronounced localisation in the nasal vestibules and lower 
regions of the nasal cavity.  For FCMC (Figure 7) this deposition area was significantly smaller 
greater than that for FCS (Figure 8).  
Interestingly, spray angles of 60° and 70° lead to deposition of the formulation in the olfactory 
regions of the nasal cavity, suggesting the possibility for exploitation in nose-to-brain delivery 
of amantadine.  FCS sprayed at an angle of 60° with insertion lead to olfactory deposition of 
0.6-0.7 cm2.  For FCMC a greater olfactory deposition of 0.91 cm2 was observed at 60° with 
insertion. Although the higher deposition for FCS may be a result of the smaller particle sizes 
for FCS (92.41 ± 1.72 µm) compared to 120.87 ± 0.59 µm, the impact of nozzle insertion for 
FCMC may enhance delivery onto the olfactory regions (Figure 7 and 8).  When considering 
the surface area of the human olfactory mucosa (2-10 cm2) 85, FCMC may be a viable candidate 
for further development targeting nose-to-brain drug delivery 86. 
In both formulations, the impact of head position (15° forward) was important in governing 
nasal depositions, leading to significantly higher deposition within the middle-upper regions 
of the cast irrespective of the insertion angle 
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The higher viscosity of FCMC compared to FCS resulted in significantly larger particle sizes 
(p < 0.001) for the optimal formulations and may have resulted in a more focussed (less 
disperse) spray plume resulting in more localised deposition patterns.  In contrast, the lower 
viscosity of FCS, leading to small particles would lead to a wider plume and greater deposition 
in the nasal cavity 87,88.  
As a viable vehicle for nasal or olfactory delivery and residency of formulations within the 
nasal cavity, the optimised formulations demonstrated rapid gelation (FCS: 36.6 s; FCMC: 28 
s) (Figure 1) with minimal displacement within the nasal cavity (FCS 0.035 cm/s; FCMC: 
0.038 cm/s) (Figure 3).  When considering their potential residency within the nasal cavity, the 
sol-gel conversion and displacement would result in minimal nasal cavity displacement (FCS: 
1.28 cm; FCMC: 1.06 cm).  In-vitro release studies were conducted for 3-hours, with the gel 
structure intact following the release studies, hence the residence in-vivo would be expected to 
be at least 3-hours.  Furthermore, the identification of potential nose-to-brain delivery, through 
olfactory deposition, would suggest that these formulations may be adapted to better exploit 
this ‘direct’ transfer route to the brain. 
CONCLUSION 
This study has investigated the potential to administer the anti-Parkinsonian drug 
amantadine through the nasal route using a mucoadhesive and thermoresponsive hydrogel 
formulation systems.  We have demonstrated that both carboxymethyl cellulose and chitosan 
can provide the requirements for mucoadhesion in these formulations, whilst also leading to a 
relatively stable formulation which can be targeted to delivery drug in specific regions of the 
nasal cavity dependant on administration angle and nozzle insertion depth.  Furthermore, our 
results have indicated the potential for nose-to-brain delivery of amantadine, yielding a 
potentially novel avenue therapeutics delivery route to avoid the blood-brain barrier. 
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List of Figures 
Figure 1: Rheological analysis of AMT containing thermoresponsive gels containing FCS, 
FPEG or FCMC. (A): Temperature sweep analyses; (B) Time-sweep analyses (fixed at 34 °C). 
Figure 2: Shear viscosity analysis of the formulations at ambient (18 °C) and nasal cavity (34 
°C) temperature. 
Figure 3: Drip transfer of optimised formulations in the presence and absence of mucin-
containing agar gel plates include at 45° to the plane and maintained at 34 °C. *** p < P 0.001.  
 
Figure 4: Amantadine cumulative % release for optimised formulations following storage at 
4°C and 25°C for up to 8 weeks. (A) Cumulative % AMT release for samples successfully 
gelling at nasal cavity temperature (34 °C); (B) Comparison of AMT release from FCMC and 
FCS at preparation (Week 0) and at the end of the stability period (Week 8). * p < 0.05, ** p 
< 0.01. 
Figure 5: Cellular toxicity of amantadine, CMC, PEG4000 and F127 on RPMI 2650 cells. 
Cells were grown on a 96-well plate and exposed to various concentrations of amantadine (0. 
1 nM – 10 mM) or polymer (10-4,000 µg/mL) for 24 hours.  Data is reported as mean ± SD 
with up to 8 replicates per compound in at least 3 independent experiments.  
 
Figure 6: Transport of AMT across an in vitro cell culture model of the nasal epithelial, from 
optimised formulations in HBSS-HEPES transport media.  ** p < 0.01. 
  
Figure 7: Representative nasal deposition patterns of FCMC. Brown colours represent the 
applied Kolor-Kut and green colours resent the depositions patterns of the spray. Angles refer 
to nasal spray position relative to the horizontal place (60, 70 or 80°), insertion of the spray 
orifice into the nostril (5 mm) or with the nasal cast angled 15° forward.   
 
Figure 8: Representative nasal deposition patterns of FCS.  Brown colours represent the 
applied Kolor-Kut and green colours resent the depositions patterns of the spray. Angles refer 
to nasal spray position relative to the horizontal place (60, 70 or 80°), insertion of the spray 
orifice into the nostril (5 mm) or with the nasal cast angled 15° forward. 
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Table 1: Power law rheological analysis of amantadine containing thermoresponsive nasal gels 
 
Formulation Temperature  (°C) k n Behaviour 
FCMC 18 0.157 0.972 Newtonian 
FPEG 18 0.0545 0.971 Newtonian 
FCS 18 0.0656 1 Newtonian 
     
FCMC 34 100.2 0.066 Non-Newtonian 
FPEG 34 13.59 0.3043 Non-Newtonian 
FCS 34 56.56 0.1762 Non-Newtonian 
 
  
Table 2:  Drug release kinetics analysis of formulations stored at ambient (18 °C) and nasal 
cavity (34 °C) temperature for up to 8 weeks.   
 Week Formulation Korsmeyer-Peppas  
4 
°C
 
0 
FCMC kKP = 2.859 ± 0.899 ; n =0.391 ± 0.051 
FPEG kKP = 2.931 ± 1.160 ; n =0.352 ± 0.076 
FCS kKP = 2.888 ± 0.632 ; n =0.684 ± 0.039 
1 
FCMC kKP = 2.004 ± 0.027 ; n =0.438 ± 0.024 
FPEG kKP = 2.012 ± 0.032 ; n =0.423 ± 0.013 
FCS kKP = 1.852 ± 0.135 ; n =0.433 ± 0.019 
8 FCMC kKP = 1.034 ± 0.170 ; n =0.538 ± 0.024 FCS kKP = 1.011 ± 0.092 ; n =0.553 ± 0.024 
25
 °C
 
1 FCS kKP = 1.997 ± 0.659 ; n =0.433 ± 0.059 
2 FCS kKP = 1.614 ± 0.351 ; n =0.474 ± 0.042 
 
kKP: Korsmeyer-Peppas constant; n= release exponent. Mean ± SD. 
 
  
Table 3. Laser diffraction particle size analysis 
 Diameter (µm)  
  Dv10 Dv50 Dv90 VMD Span 
FCS 7.27 ± 0.28 109.07 ± 3.42 157.77 ± 0.99 92.41 ± 1.72 1.38 ± 0.21 
FCMC 39.81 ± 1.02 129.86 ± 0.29 167.39 ± 0.09 120.87 ± 0.59 0.98 ± 0.30 
FPEG 43.93 ± 0.88 104.67 ± 1.88 150.95 ± 1.04 100.35 ± 1.53 1.02 ± 0.06 
Mean ±SD, 6 replicate spray actuations per formulation. 
Dv10: 10 % of the cumulative undersized (volume) fraction; Dv50: 50 % of the cumulative 
undersized (volume) fraction; Dv90: 90 % of the cumulative undersized (volume) fraction; 
VMD: volume mean diameter; Span: relative span (Dv90-Dv10)/Dv50. 
 
